ISSN: 2376-127X

Zeitschrift für Schwangerschaft und Kindergesundheit

Offener Zugang

Unsere Gruppe organisiert über 3000 globale Konferenzreihen Jährliche Veranstaltungen in den USA, Europa und anderen Ländern. Asien mit Unterstützung von 1000 weiteren wissenschaftlichen Gesellschaften und veröffentlicht über 700 Open Access Zeitschriften, die über 50.000 bedeutende Persönlichkeiten und renommierte Wissenschaftler als Redaktionsmitglieder enthalten.

Open-Access-Zeitschriften gewinnen mehr Leser und Zitierungen
700 Zeitschriften und 15.000.000 Leser Jede Zeitschrift erhält mehr als 25.000 Leser

Abstrakt

The Effect of a Novel Multi-Ingredient Supplement in Pregnant Women

Marco Rigatti, Agostino Menditto, Renato De Stefano, Civetta Antonio, Umberto Landri, Roberto Passaro, Mario Passaro, Fabrizio Paolillo Diodati, Alessandro Nicotra, Emio Cafarelli, Ermanno Barletta, Antonio Esposito, Pierluigi Pozzuoli

Objective: to investigate the effects of a novel multi-ingredient supplement comprised of high dose whey protein, to improve maternal and perinatal outcomes in pregnant women

Methods: This was an observational retrospective study. Women who received oral supplementation with a novel multi-ingredient supplement (PSIPROTO ®), comprised of high dose whey protein, were compared with women who did not. Inclusion criteria were singleton pregnancy with body mass index (BMI) higher than 25. The primary outcome of the study was the incidence of adverse pregnancy outcome

Results: 400 women, 200 for each group, were included in the study. The two groups were similar in terms of maternal demographics, and both of them had similar BMI. Maternal age and smoking rate were also similar. Women who received the intervention had a significantly lower maternal weight gain, and lower risk of low birth weight. Notably, 4 women in the intervention group reported intrauterine growth restriction before the intervention, and solved after 2 months of supplementation.

Conclusion: Our retrospective cohort of singleton gestations with BMI >25 showed that PSIPROTO is a safe and efficacy supplement in pregnancy.

Haftungsausschluss: Dieser Abstract wurde mit Hilfe von Künstlicher Intelligenz übersetzt und wurde noch nicht überprüft oder verifiziert.